Ergonovine
PubChem records this structure as Ergometrine.
Also known asErgometrine · Ergobasine · Ergotocine · Ergostetrine · Margonovine · Ergoklinine · Ergometrin · Ergometrina
(6aR,9R)-N-[(2S)-1-hydroxypropan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
- PubChem CID
- 443884
- ChEMBL
- CHEMBL119443
- Measurements
- 28
- InChIKey
- WVVSZNPYNCNODU-XTQGRXLLSA-N
I · Summary
What is known
Published passages, each quoted whole and attributed to the database that published it. Two blocks are written here rather than quoted, and both say so where they stand: the synthesized summary at the top, which may draw only on the passages beneath it, and the history note, which cites the works it came from. Every claim in either carries a marker to its source.
What it is
Ergometrine is a monocarboxylic acid amide that is lysergamide in which one of the hydrogens attached to the amide nitrogen is substituted by a 1-hydroxypropan-2-yl group (S-configuration). An ergot alkaloid that has a particularly powerful action on the uterus, its maleate (and formerly tartrate) salt is used in the active management of the third stage of labour, and to prevent or treat postpartum of postabortal haemorrhage caused by uterine atony: by maintaining uterine contraction and tone, blood vessels in the uterine wall are compressed and blood flow reduced. It has a role as a toxin, a diagnostic agent, an oxytocic and a fungal metabolite. It is a primary alcohol, an ergot alkaloid, a…
An ergot alkaloid with uterine and vascular smooth muscle contractile properties.
ergometrine has been reported in Balansia claviceps, Balansia epichloe, and other organisms with data available.
Ergonovine is only found in individuals that have used or taken this drug. It is an ergot alkaloid with uterine and vascular smooth muscle contractile properties. [PubChem] Ergonovine directly stimulates the uterine muscle to increase force and frequency of contractions. With usual doses, these contractions precede periods of relaxation; with larger doses, basal uterine tone is elevated and these relaxation periods will be decreased. Contraction of the uterine wall around bleeding vessels at the placental site produces hemostasis. Ergonovine also induces cervical contractions. The sensitivity of the uterus to the oxytocic effect is much greater toward the end of pregnancy. The oxytocic actio…
Recognized use
Ergonovine maleate and methylergonovine maleate are used for the prevention and treatment of postpartum hemorrhage caused by uterine atony. The drugs appear to be equally effective for these purposes; however, many clinicians prefer methylergonovine to ergonovine because the former drug may produce hypertension less frequently than does the latter drug. /Not included in US product label/
Therapeutic Uses
Hazardous Substances Data Bank (HSDB)American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 3307
Ergonovine maleate has been used as a provocative test for the diagnosis of variant angina. The drug has been used to precipitate coronary artery spasm in patients with suspected variant angina. /Not included in US product label/
Therapeutic Uses
Hazardous Substances Data Bank (HSDB)American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 3307
Ergonovine and methylergonovine should not be used for the induction or augmentation of labor.
Therapeutic Uses
Hazardous Substances Data Bank (HSDB)American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 3307
MEDICATION (VET): Oxytocic ... /used/ in control of postpartum uterine hemorrhage, removal of fluid from atonic uteri, to help prevent prolapsed uteri, and judiciously in terms of timing to aid in suturing uterus after cesarean section or in replacing everted uterus.
Therapeutic Uses
Hazardous Substances Data Bank (HSDB)Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 197
Used to treat postpartum haemorrhage and postabortion haemorrhage in patients with uterine atony.
Drug Indication
Ergoline alkaloids occur in various species of vines of the Convolvulaceae (morning glory) family and in some species of lower fungi. Ergometrine can also be synthesized from (+)-lysergic acid and L-(+)-2-aminopropanol. It has medical use in obstetrics to facilitate delivery of the placenta and to prevent bleeding after childbirth by causing smooth muscle tissue in the blood vessel walls to narrow, thereby reducing blood flow. For this is usually combined with oxytocin (Syntocinon) as syntometrine. (L1918, L1922)
Use Classification
How it acts
Ergonovine directly stimulates the uterine muscle to increase force and frequency of contractions. With usual doses, these contractions precede periods of relaxation; with larger doses, basal uterine tone is elevated and these relaxation periods will be decreased. Contraction of the uterine wall around bleeding vessels at the placental site produces hemostasis. Ergonovine also induces cervical contractions. The sensitivity of the uterus to the oxytocic effect is much greater toward the end of pregnancy. The oxytocic actions of ergonovine are greater than its vascular effects. Ergonovine, like other ergot alkaloids, produces arterial vasoconstriction by stimulation of alpha-adrenergic and ser…
Ergonovine maleate and methylergonovine maleate are pharmacologically similar. Both drugs directly stimulate contractions of uterine and vascular smooth muscle. Following administration of usual therapeutic doses of ergonovine or methylergonovine, intense contractions of the uterus are produced and are usually followed by periods of relaxation. Larger doses of the drugs, however, produce sustained, forceful contractions followed by only short or no periods of relaxation. The drugs increase the amplitude and frequency of uterine contractions and uterine tone which in turn impede uterine blood flow. Ergonovine and methylergonovine also increase contractions of the cervix.
Hazardous Substances Data Bank (HSDB)American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 3308
Behavior carries the pharmacological classes and the acute-effect durations, with plasma half-life kept separate from duration of effect.
In the body
Absorption is rapid and complete after oral or intramuscular administration.
Absorption, Distribution and Excretion
Thought to be eliminated by non-renal mechanisms (i.e. hepatic metabolism, excretion in feces)
Absorption, Distribution and Excretion
Ergonovine maleate and methylergonovine maleate are rapidly absorbed after oral or im administration.
Absorption, Distribution and Excretion
Hazardous Substances Data Bank (HSDB)American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 3308
Uterine contractions are usually initiated within 5-15 minutes following oral administration, within 2-5 minutes after im injection, and immediately following iv injection of ergonovine or methylergonovine. Uterine contractions persist for 3 hours or longer after oral or im administration and for 45 minutes after iv injection of either drug.
Absorption, Distribution and Excretion
Hazardous Substances Data Bank (HSDB)American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 3308
Hepatic. Route of Elimination: Thought to be eliminated by non-renal mechanisms (i.e. hepatic metabolism, excretion in feces) Half Life: t1/2 α=10 minutes; t1/2 β=2 hours
Metabolism/Metabolites
History, discovery and cultural use
— Not in this archive. PubChem, ChEMBL and the Human Protein Atlas publish pharmacology, regulation and toxicology, and none of them publishes a heading for when Ergonovine was first made, by whom, or how it has been used. That is a gap in the databases this site reads and not a gap in the literature — the history of these compounds is written, at length and under peer review, in the works below. This site does not summarize them; it says where they are. Where a published passage above happens to touch origin or traditional use, it appears inside the entry that carries it.
Histories of this field
Scholarship on psychedelics generally, not on Ergonovine specifically. Whether any of these treats this compound is a question for the book, not for this page.
Mescaline: A Global History of the First Psychedelic
Traces mescaline and the peyote and San Pedro cacti from pre-Columbian ritual use through nineteenth-century chemistry to twentieth-century psychiatry and the counterculture.
Jay M. Mescaline: A Global History of the First Psychedelic. Yale University Press, New Haven and London; 2019. ISBN 9780300231076.
Expanding Mindscapes: A Global History of Psychedelicsopen access
Essays on the international and cross-cultural history of psychedelic science, deliberately decentring the standard North American and European account.
Dyck E, Elcock C, editors. Expanding Mindscapes: A Global History of Psychedelics. The MIT Press, Cambridge MA; 2023. ISBN 9780262546935 (paper), 9780262376891 (open access). doi:10.7551/mitpress/14417.001.0001.
Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers
Botany, ethnography and chemistry of the principal hallucinogenic plants, by the founder of modern ethnobotany and the chemist who first synthesized LSD.
Schultes RE, Hofmann A, Rätsch C. Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers. 2nd ed. Healing Arts Press, Rochester VT; 2001. ISBN 9780892819799.
Psychonauts: Drugs and the Making of the Modern Mind
The tradition of scientific self-experimentation with psychoactive drugs, and its part in the emergence of psychology and of modernism.
Jay M. Psychonauts: Drugs and the Making of the Modern Mind. Yale University Press, New Haven; 2023. ISBN 9780300257946.
Ancient Psychoactive Substances
Archaeological and bioarchaeological evidence for psychoactive plant use across the ancient world.
Fitzpatrick SM, editor. Ancient Psychoactive Substances. University Press of Florida, Gainesville; 2018. ISBN 9780813056708.
A chapter tracing psychedelic and entactogen research from earlier ritual use through the mid-century research period to current clinical trials.
Stroud C, Posey Norris SM, Matney C, editors. History and Current Status of Psychedelics and Entactogens for the Treatment of Psychiatric Disorders. In: Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. National Academies Press, Washington DC; 2022. NBK587225.
Workshop proceedings record what participants said; they are not a consensus statement of the National Academies.
Peer-reviewed review covering the isolation, synthesis, pharmacology and ritual use of peyote and mescaline.
Dinis-Oliveira RJ, Pereira CL, da Silva DD. Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions. Current Molecular Pharmacology 12(3):184–194; 2019. doi:10.2174/1874467211666181010154139.
Institutional archives
- Heffter Research Institute Funds and coordinates clinical research on psilocybin, and keeps records of the studies it has supported since 1993. Sponsors the research it archives.
- Multidisciplinary Association for Psychedelic Studies (MAPS) Sponsors clinical research, chiefly on MDMA-assisted therapy, and publishes an archive of historical and contemporary documents. A sponsor and an advocacy organization, not a disinterested archive; its clinical programme has a commercial arm.
The rest of this dossier
- Affinity — 28 measurements in this archive, equilibrium constants kept apart from functional readouts.
- Toxicology — 6 published passages, plus any assay in this archive bearing on toxicity.
- Legal — listed by the DEA among its drugs of concern, with no schedule stated in the record held here.
- Systems — where this compound’s targets are transcribed, by brain region and tissue.
Passages via PubChem descriptive sections, aggregating DrugBank, LiverTox, FDA, DEA, HSDB, EPA. Each is quoted whole and attributed to the database that published it. The only prose written here about Ergonovine is the history note, which says so on its face and carries a reference for every claim in it.
II · Identity
Structure and descriptors
Descriptors are computed here with RDKit from the structure PubChem returns — not from the archive's stored copy, so an edited local structure cannot reach this table.
- Formula
- C19H23N3O2R
- Molecular weight
- 325.41g/molR
- Exact mass
- 325.1790DaR
- cLogP
- 1.53R
- TPSA
- 68.4ŲR
- H-bond donors
- 3R
- H-bond acceptors
- 3R
- Rotatable bonds
- 3R
- Aromatic rings
- 2R
- Heavy atoms
- 24R
- Fraction sp³
- 0.421R
- Formal charge
- 0R
Computed with RDKit 2025.09.2 from the SMILES returned by PubChem. Audit run 26/09/2026.
Bemis–Murcko scaffold
C1=C2c3cccc4[nH]cc(c34)C[C@H]2NCC1
Shared with 1B-LSD, 1DD-LSD, 1H-LSD, 1P-AL-LAD, 1P-ETH-LAD, 1P-LSD and 23 more. All families
III · Behavior
Behavioral summary
Class, mechanism, and the duration of acute effects — each quoted from the record or trial that publishes it. Duration of effects and plasma half-life are shown separately, because they are different quantities and diverge by a factor of three or four.
Classification
Duration of acute subjective effects
—
No controlled human trial reporting a duration for this compound is cited here. The archive holds no other record of one either. A duration is not inferred from a chemical relative.
Plasma elimination half-life
How fast the body clears the drug — not how long the effects last. The two diverge sharply: LSD is cleared with a half-life of about 2.6 h while its subjective effects run 8–12 h.
The aim of this investigation was to assess the pharmacokinetics and bioavailability of ergometrine in six human male subjects after an oral dose of 0.200 mg and after an intravenous dose of 0.075 mg of ergometrine maleat. ... After intravenous administration, the pharmacokinetic profile can be described by a two-compartment model. The d…
Hazardous Substances Data Bank (HSDB)PMID 8161717de Groot AN et al; Biopharm Drug Dispos 15 (1): 65-73 (1994) t1/2 α=10 minutes; t1/2 β=2 hours
DrugBank Plasma concentrations of methylergonovine appear to decline in a biphasic manner. ... Following iv administration of ergonovine to adults, the half-life of the drug in the initial phase (t1/2 alpha) reportedly is about 10 minutes and the half-life in the terminal phase (t1/2 beta) is about 2 hours.
Hazardous Substances Data Bank (HSDB)American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 3308
Primary pharmacological drivers
ChEMBL holds no curated mechanism-of-action record for this compound. The measured affinities below are the evidence this archive has for what it binds.
Mechanism, as published
Quoted verbatim from the database named after each passage, never summarized.
... The effect of /Ergonovine/ on isolated canine tracheobronchial smooth muscle was analyzed to investigate the mechanism of ergonovine-induced airway smooth muscle contraction. Both ergonovine and serotonin (5-hydroxytryptamine, 5HT) contracted canine tracheal smooth muscle with EC50 1.4 X 10(-8) M and 5.1 X 10(-7) M, respectively. The…
Hazardous Substances Data Bank (HSDB)PMID 2796062Sakamoto Y; Nihon Kyobu Shikkan Gakkai Zasshi 27 (6): 679-88 (1989) Ergonovine directly stimulates the uterine muscle to increase force and frequency of contractions. With usual doses, these contractions precede periods of relaxation; with larger doses, basal uterine tone is elevated and these relaxation periods will be decreased. Contraction of the uterine wall around bleeding vessels at the placental si…
DrugBank Ergonovine maleate and methylergonovine maleate are pharmacologically similar. Both drugs directly stimulate contractions of uterine and vascular smooth muscle. Following administration of usual therapeutic doses of ergonovine or methylergonovine, intense contractions of the uterus are produced and are usually followed by periods of relax…
Hazardous Substances Data Bank (HSDB)American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 3308 Ergonovine and methylergonovine produce vasoconstriction, mainly of capacitance vessels; increased central venous pressure, elevated blood pressure, and, rarely, peripheral ischemia and gangrene may result. Methylergonovine reportedly may interfere with prolactin secretion, but this effect has not been definitely established.
Hazardous Substances Data Bank (HSDB)American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011, p. 3308 Ergonovine belongs to the group of medicines known as ergot alkaloids. These medicines are usually given to stop excessive bleeding that sometimes occurs after abortion or a baby is delivered. They work by causing the muscle of the uterus to contract.
DrugBank
IV · Clinical
Clinical description
Where this compound's substance class sits in ICD-11 and DSM-5-TR, and how much of the recorded literature speaks to each domain of a mental status examination.
No diagnostic chapter is shown for this compound. Either PubChem records no MeSH pharmacological class for it, or the class it records is not one of the substance classes ICD-11 gives a chapter to. Inferring a chapter from the compound’s name or its binding profile would be a diagnosis this archive is in no position to make.
How much has been written about each domain
The clinical domains, and how many of the records this archive holds for this compound say something under each. What the terms mean, and the word list behind every spoke, are set out in the method.
- Mood 1
- matched on “depression” · in PMID 2805461
- Perception 1
- matched on “hallucinat” · in Toxicology: Toxin and Toxin Target Database (T3DB)
- Cognition 1
- matched on “concentrat” · in Pharmacology: Biological Half-Life
V · Systems
Systems physiology
Where the targets this compound binds are transcribed — brain regions on the left, peripheral and autonomic tissues on the right. A join of two measurements, not a claim about what the compound does to either.
Brain
basal ganglia: drawn as the caudate nucleus, putamen and globus pallidus.
Measured but not drawn — this anatomogram has no outline for them: pituitary gland 56.6, midbrain 23.4, retina 10.8, spinal cord 1.3.
Body
Square-root ramp · shared scale across both plates
Shading is transcript level — not affinity, and not affinity combined with expression. Outlined but unshaded organs hold none of this compound’s resolved targets above the atlas’s detection threshold. Anatomy from EMBL-EBI Anatomogram (Apache License 2.0); regions identified by Uberon (uberon.org), CC BY 3.0.
Brain regions
Regions where this compound's measured targets are transcribed. Linked from the plate above.
basal ganglia
62.0 nTPMpituitary gland
56.6 nTPMmidbrain
23.4 nTPMcerebral cortex
18.2 nTPMhypothalamus
12.6 nTPMretina
10.8 nTPMhippocampal formation
6.1 nTPMcerebellum
5.8 nTPMamygdala
3.5 nTPMspinal cord
1.3 nTPM
Peripheral & autonomic
Tissues outside the CNS expressing the same targets — where a compound's bodily effects become possible.
pancreas
28.8 nTPMadrenal gland
17.2 nTPMsmooth muscle
15.7 nTPMurinary bladder
14.8 nTPMspleen
13.1 nTPMsalivary gland
11.3 nTPMheart muscle
9.4 nTPMduodenum
9.4 nTPMthyroid gland
8.7 nTPMcolon
8.5 nTPMkidney
7.8 nTPMliver
6.3 nTPMskeletal muscle
6.0 nTPMsmall intestine
5.0 nTPMstomach 1
4.7 nTPMlung
4.3 nTPM
Each row joins two published measurements and nothing else: the affinity this archive holds for the compound at that target, and the transcript level the Human Protein Atlas reports for that target’s gene in that region. Bars scale with expression only. Expression is not activation — a receptor transcribed in a region is a receptor available to be bound there, which is a weaker and more defensible claim than saying the region is affected.
Expression data from Human Protein Atlas (CC BY-SA 3.0), RNA expression, nTPM (normalized transcripts per million), consensus tissue dataset. Uhlén M, et al. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.
VI · Profile
Affinity rosette
The strongest measurement at each of 12 molecular targets. Cell-line and whole-organism screens are excluded here — they carry no affinity — and appear in the table below.
VII · Toxicology
Toxicological profile
What has been measured, and what has been published — kept apart, and neither scored. There is no risk rating on this page; the archive once carried one, identical for every compound, produced by a stub.
Measured in this archive
Assays that bear on toxicity, drawn from the same ChEMBL records as everything else on this page. They are measurements of what a compound binds or does to cells — not verdicts about what it does to a person.
No hERG, cytochrome, cytotoxicity or transport measurement exists for Ergonovine in this archive.
As published
Quoted verbatim from the database named after each passage, never summarized — a summary of a toxicology statement is a new claim.
Toxicity Summary
Ergoline alkaloids tend to act as a group, producing complex and variable effects of partial agonism or antagonism at adrenergic, dopaminergic, and serotonergic receptors. Variables relating to these effects are influenced by the agent, dosage, species, tissue, physiological, and endocrinological state, and experimental conditions. In particular, ergoline alkaloids have been shown to have the significant affinity tow…
Human Toxicity Excerpts
/HUMAN EXPOSURE STUDIES/ ...The ergonovine provocation test was performed in 419 patients with suspected but unproven variant angina. Ergonovine maleate was administered into the coronary arteries at 8 ug/min for 5 min during cardiac catheterization. Patients were categorized into three groups according to their response to ergonovine. The positive group contained patients who developed coronary constriction of more…
Hazardous Substances Data Bank (HSDB)PMID 11433805Kashima K et al; J Cardiol 37 (6): 301-8 (2001)
/HUMAN EXPOSURE STUDIES/ To assess the local and systemic intracoronary (IC) ergonovine maleate (EM), single or repeated 25 ug bolus injections were administered to 108 consecutive patients with chest pain and normal coronary arteriograms. Coronary artery spasm (CAS) was induced in 17 (15.7%) patients. None of these patients developed ST-segment depression, and ST-segment elevation appeared in only 6 (35.3%). In 59 o…
Hazardous Substances Data Bank (HSDB)PMID 2805461Fournier JA et al; Clin Cardiol 12 (10): 561-8 (1989)
/HUMAN EXPOSURE STUDIES/ Blood loss and frequency of vomiting assessed at 88 spontaneous vertex deliveries. Vomiting and retching occurred in 13% of mothers given ergometrine iv but not in those given oxytocin.
Hazardous Substances Data Bank (HSDB)MOIR DD, AMOA AB; BR J ANAESTH 51(2) 113-117 (1979)
/HUMAN EXPOSURE STUDIES/ Administration of 0.2 mg ergonovine maleate orally on 3rd day postpartum to women caused decreases in circulating prolactin levels. Postpartum administration of this drug may interfere with lactation.
Hazardous Substances Data Bank (HSDB)SHANE JM, NAFTOLIN F; AM J OBSTET GYNECOL 120(1) 129-131 (1974)
For more Human Toxicity Excerpts (Complete) data for ERGONOVINE (18 total), please visit the HSDB record page.
Published passages via PubChem toxicology sections, aggregating Hazardous Substances Data Bank (HSDB), RTECS, LiverTox. No figure on this page is scored, ranked or combined into a risk level.
VIII · Evidence
Every measurement
One row per published value. The identifier in the last column resolves to the ChEMBL assay record it was read from.
Equilibrium binding constants 16
Ki and Kd — a concentration at equilibrium. Directly comparable across rows at the same target.
| Target | Class | Type | Value (nM) | pX | Organism | Assay |
|---|---|---|---|---|---|---|
| 5-HT2A | Serotonin receptors | Ki | 0.630 | 9.20 | Homo sapiens | CHEMBL1909211 |
| 5-HT1B | Serotonin receptors | Ki | 1.29 | 8.89 | Rattus norvegicus | CHEMBL1909210 |
| 5-HT6 | Serotonin receptors | Ki | 1.50 | 8.82 | Homo sapiens | CHEMBL1909108 |
| 5-HT2B | Serotonin receptors | Ki | 2.63 | 8.58 | Homo sapiens | CHEMBL1909104 |
| 5-HT1A | Serotonin receptors | Ki | 4.64 | 8.33 | Rattus norvegicus | CHEMBL1909209 |
| 5-HT2C | Serotonin receptors | Ki | 11.00 | 7.96 | Homo sapiens | CHEMBL1909105 |
| 5-HT2C | Serotonin receptors | Ki | 31.60 | 7.50 | PIG | PDSP |
| D1 | Dopamine receptors | Ki | 61.00 | 7.21 | CALF | PMID 995128 |
| 5-HT1E | Serotonin receptors | Ki | 87.09 | 7.06 | HUMAN | PMID 7984267 |
| 5-HT1E | Serotonin receptors | Ki | 88.00 | 7.06 | HUMAN | PMID 1513320 |
| Alpha2B | Adrenergic receptors | Ki | 132 | 6.88 | Homo sapiens | CHEMBL1909089 |
| D2 | Dopamine receptors | Ki | 184 | 6.74 | Homo sapiens | CHEMBL1909140 |
| D3 | Dopamine receptors | Ki | 193 | 6.71 | Homo sapiens | CHEMBL1909141 |
| Alpha2A | Adrenergic receptors | Ki | 630 | 6.20 | Homo sapiens | CHEMBL1909088 |
| Unchecked | Unclassified | Ki | 1,228 | 5.91 | — organism not recorded | CHEMBL1909159 |
| D1 | Dopamine receptors | Ki | 2,950 | 5.53 | Homo sapiens | CHEMBL1909139 |
Functional readouts 12
IC₅₀, EC₅₀, AC₅₀ and potency. Assay-dependent, and not interchangeable with a binding constant.
| Target | Class | Type | Value (nM) | pX | Organism | Assay |
|---|---|---|---|---|---|---|
| 5-HT2A | Serotonin receptors | IC50 | 2.21 | 8.66 | Homo sapiens | CHEMBL1909211 |
| 5-HT1B | Serotonin receptors | IC50 | 2.85 | 8.55 | Rattus norvegicus | CHEMBL1909210 |
| 5-HT6 | Serotonin receptors | IC50 | 3.24 | 8.49 | Homo sapiens | CHEMBL1909108 |
| 5-HT2B | Serotonin receptors | IC50 | 4.14 | 8.38 | Homo sapiens | CHEMBL1909104 |
| 5-HT1A | Serotonin receptors | IC50 | 8.13 | 8.09 | Rattus norvegicus | CHEMBL1909209 |
| 5-HT2C | Serotonin receptors | IC50 | 21.00 | 7.68 | Homo sapiens | CHEMBL1909105 |
| Alpha2B | Adrenergic receptors | IC50 | 289 | 6.54 | Homo sapiens | CHEMBL1909089 |
| D2 | Dopamine receptors | IC50 | 552 | 6.26 | Homo sapiens | CHEMBL1909140 |
| D3 | Dopamine receptors | IC50 | 567 | 6.25 | Homo sapiens | CHEMBL1909141 |
| Alpha2A | Adrenergic receptors | IC50 | 1,680 | 5.77 | Homo sapiens | CHEMBL1909088 |
| Unchecked | Unclassified | IC50 | 1,843 | 5.73 | — organism not recorded | CHEMBL1909159 |
| D1 | Dopamine receptors | IC50 | 5,901 | 5.23 | Homo sapiens | CHEMBL1909139 |
- P
- PubChem
- C
- ChEMBL
- R
- Computed here with RDKit
- D
- Derived here from the stored measurement
IX · Trials
Registered clinical trials
Studies filed with ClinicalTrials.gov that name this compound as an intervention. A registered trial is a protocol, not a result — status and enrollment are printed beside every row, and withdrawn studies are counted rather than hidden.
10T
Registered studies
1T
Open or ongoing
10T
With a phase recorded
By phase
A study may carry two phase codes at once, so these count studies bearing each phase and do not sum to the total.
- Phase 32
- Phase 42
- Not applicable6
By status
The registry’s own status for each record. Withdrawn and terminated studies are counted here rather than hidden — a stopped trial is part of what is known.
- Completed5
- Unknown status4
- Recruiting1
Every matched study
Newest first by start date. Each identifier opens the registry record it came from; the title is the sponsor’s own, quoted.
- NCT06285409Recruiting · Not applicable
Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium
- Enrollment
- 32Testimated
- Started
- 2024-04-04
- Sponsor
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Conditions Postpartum Hemorrhage
Matched “Ergonovine” in the study’s intervention “Ergonovine”
- NCT04300452Unknown status · Phase 4
Carbetocin Versus Ergometrin in the Prevention of Postpartum Hemorrhage
- Enrollment
- 100Testimated
- Started
- 2018-04-05
- Sponsor
- National and Kapodistrian University of Athens
Conditions Postpartum Hemorrhage
Matched “Ergometrine” in the study’s intervention “Ergometrine Maleate”
- NCT03578263Completed · Not applicable
Carbetocin Versus Oxytocin and Ergometrine for the Prevention of Postpartum Hemorrhage
- Enrollment
- 220Tactual
- Started
- 2018-04-01
- Sponsor
- Aswan University Hospital
Conditions Cesarean Section Complications
Matched “Ergometrine” in the study’s intervention “ergometrine”
- NCT02410759Unknown status · Phase 3
Carbetocin Versus Ergometrine in the Management of Atonic Post Partum Haemorrhage (PPH) in Women Delivered Vaginally
- Enrollment
- 200Testimated
- Started
- 2015-04
- Sponsor
- Cairo University
Conditions Post Partum Hemorrhage
Matched “Ergometrine” in the study’s intervention “Ergometrine”
- NCT02306733Unknown status · Phase 3
Ergometrine Versus Oxytocin in the Management of Atonic Post-partum Haemorrhage (PPH) in Women Delivered Vaginally
- Enrollment
- 200Testimated
- Started
- 2014-11
- Sponsor
- Cairo University
Conditions Post Partum Hemorrhage
Matched “Ergometrine” in the study’s intervention “Ergometrine”
- NCT02046499Completed · Not applicable
A Randomized Trial Comparing Oxytocin and Oxytocin + Ergometrine for Prevention of Postpartum Haemorrhage at Caesarean Section
- Enrollment
- 540Tactual
- Started
- 2014-01-01
- Sponsor
- University of Pretoria
Conditions Prevention of Post Partum Haemorrhage
Matched “Ergometrine” in the study’s intervention “Oxytocin ergometrine”
- NCT01236482Unknown status · Phase 4
Oxytocin in Cesarean Delivery
- Enrollment
- 80Testimated
- Started
- 2010-11
- Sponsor
- Hadassah Medical Organization
Conditions Post Partum Hemorrhage
Matched “Ergometrine” in the study’s intervention “Oxytocin versus oxytocin-ergometrine”
- NCT01689311Completed · Not applicable
In Vitro Myometrial Contractions in Laboring and Non-laboring Women
- Enrollment
- 53Tactual
- Started
- 2009-03
- Sponsor
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Conditions Postpartum Hemorrhage
Matched “Ergonovine” in the study’s intervention “Ergonovine”
- NCT00989027Completed · Not applicable
Impact of Uterotonic Agents on Isolated Human Myometrium
- Enrollment
- 56Tactual
- Started
- 2007-06
- Sponsor
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Conditions Postpartum Hemorrhage
Matched “Ergonovine” in the study’s intervention “Ergonovine”
- NCT00481533Completed · Not applicable
Ergot and Oxytocin During Cesarean Delivery Following Failure to Progress in Labour
- Enrollment
- 47Tactual
- Started
- 2005-06
- Sponsor
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Conditions Blood Loss, Surgical
Matched “Ergonovine” in the study’s intervention “Methyl-Ergonovine-Oxytocin”
Records from ClinicalTrials.gov (U.S. National Library of Medicine, NIH), API v2. A study is listed against a compound only when a verified name for that compound appears as a whole word in one of the study's own intervention names. A short code must appear as written, and a name the registry uses for something else (Aleph, a vaccine maker) is not matched. Title matches are not accepted. The matched name and the intervention text it matched are shown with every row.
Searched as Ergonovine · Ergometrine · Ergobasine. Run this search at the registry — it returns the unfiltered result, including studies this page rejected as belonging to a different molecule.
A registered trial is a protocol somebody filed with the registry. It is not a result, and nothing on this plate says whether Ergonovine worked.
X · Legal
Controlled-substance status
United States federal scheduling, read from the DEA records this archive holds and shown with the passage each was read from. Not legal advice, and not necessarily current.
As the DEA states it
Quoted whole. The badge above is a reading of these passages and adds nothing to them.
List I Chemical: A chemical specified by regulation that, in addition to legitimate uses, is used in manufacturing a controlled substance in violation of the Act and is important to the manufacture of a controlled substance. (21 eCFR 1310.02)
Drug Enforcement Administration (DEA)21 CFR Section 1310.02(a) https://www.ecfr.gov/current/title-21/chapter-II/part-1310/section-1310.02
United States federal status only. State law differs, and so does the law of every other country — none of it is represented here. Scheduling changes, and this reflects the DEA records held by PubChem descriptive sections when the monograph was last harvested, not necessarily today. This is a record of what a database publishes, not legal advice.
XI · Literature
Sources behind this dossier
The papers this compound's values were read from, ranked by what each contributed. Not a review of the field.
Every paper below is one some value on this page came from — a binding constant, a passage of pharmacology or toxicology, or a measured duration. Each entry says what this archive took from it. Nothing else is claimed about any of them: the title is the study’s own account of itself, and a summary written here would be an assertion with no source behind it.
- 01
Molecular biology of 5-HT receptors
Boess FG, Martin IL · Neuropharmacology 1994
- · 1 measurement at 1 target (Ki), strongest 5-HT1E at 7.06 pX
- 02
Human gene S31 encodes the pharmacologically defined serotonin 5-hydroxytryptamine1E receptor
Zgombick JM, Schechter LE, Macchi M et al. · Molecular pharmacology 1992
- · 1 measurement at 1 target (Ki), strongest 5-HT1E at 7.06 pX
- 03
Burt DR, Creese I, Snyder SH · Molecular pharmacology 1976
- · 1 measurement at 1 target (Ki), strongest D1 at 7.21 pX
- 04
Kashima K, Tachibana H, Nakamura K et al. · Journal of cardiology 2001
- · Human Toxicity Excerpts
- 05
Pharmacokinetics and bioavailability of oral ergometrine in male volunteers
de Groot AN, Vree TB, Hekster YA et al. · Biopharmaceutics & drug disposition 1994
- · Biological Half-Life
- 06
[The mechanism of ergonovine-induced airway smooth muscle contraction]
Sakamoto Y · Nihon Kyobu Shikkan Gakkai zasshi 1989
- · Mechanism of Action
- 07
Fournier JA, Cortacero JA, Turá A et al. · Clinical cardiology 1989
- · Human Toxicity Excerpts